

Press release 8 July 2008



## FDA approves azelastine eye drops unit dose

The U.S. Food and Drug Administration (FDA) has approved Meda's registration application for azelastine eye drops in unit dose (Optivar Unit Dose). The substance azelastine is an antihistamine and the eye drop formulation is approved for treatment of allergic conjunctivitis in adults and pediatrics.

Meda is conducting a broad development program for the azelastine substance, both as azelastine eye drops and azelastine nasal spray. Azelastine eye drops sample is one part of that development program.

---

For more information contact:

Anders Larnholt, VP Investor Relations

phone. +46 709 458 878, or +46 8 630 19 62

---

**MEDA AB (publ)** is an international specialty pharma company that concentrates on marketing and market-adapted product development. Acquisitions and long-term partnerships are fundamental factors that drive the company's strategy. Meda is represented by its own organisations in 26 countries and has more than 1 500 employees within marketing and sales. Meda's products are sold in about 120 countries worldwide. The Meda share is listed under Large Cap on the OMX Nordic Stock Exchange. Find out more, visit [www.meda.se](http://www.meda.se).